ABSTRACT
Abstract Objective: To explore the changes and clinical significance of serum Neuron-Specific Enolase (NSE) and Squamous Cell Carcinoma antigen (SCC) in patients with lung cancer before and after radiotherapy. Methods: 82 patients with lung cancer were treated with radiotherapy, and effective clinical intervention was given during the radiotherapy process. The patients were followed up for 1 year after radiotherapy and were divided into a recurrence and metastasis group (n = 28) and a non-recurrence and metastasis group (n = 54) according to their prognosis. Another 54 healthy volunteers examined in the present study's hospital during the same period were selected as the control group. To compare the changes of NSE and SCC levels in serum in patients with lung cancer at admission and after radiotherapy, and to explore their clinical significance. Results: After intervention, NSE and SCC levels in the serum of the two groups of patients were significantly lower than those before intervention, and the levels of CD4+ and CD4+/CD8+ were significantly higher than those before intervention (p < 0.05); the level of CD8+ was not significantly different from that before intervention (p > 0.05). And NSE and SCC levels in the intervention group were significantly lower than those in the routine group, the levels of CD4+, CD4+/CD8+ were significantly higher than those in the routine group (p < 0.05). Conclusion: NSE and SCC in serum can preliminarily evaluate the effect of radiotherapy in patients with lung cancer and have a certain predictive effect on prognosis.
ABSTRACT
Objective:To investigate the relationship between tumor volume changes, squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and the prognosis of cervical cancer patients with concurrent radiotherapy and chemotherapy and their combined prediction of prognosis.Methods:One hundred and twenty-eight patients in Shanxi Cancer Hospital from February 2018 to February 2020, with cervical cancer undergoing radical concurrent radiotherapy and chemotherapy were selected for a prospective study. According to different prognostic effects, the patients were divided into poor prognosis group (44 cases) and good prognosis group (84 cases). The general data, tumor reduction rate (TVRR), SCC-Ag, CEA, and CA125 levels were compared between the two groups, and the Logistic regression equation was used to analyze the prognostic factors of patients with concurrent radiotherapy and chemotherapy for cervical cancer. The receiver operating characteristic (ROC) curve and the area under the curve (AUC) were used to analyze the performance of each index and the joint prediction of prognosis. Kaplan-Meier survival curve analysis and log-rank (Mantel-Cox) were used to test the survival curves of TVRR, SCC-Ag, CEA, CA125 high-risk individuals and low-risk individuals.Results:The TVRR in the poor prognosis group was significantly lower than that in the good prognosis group: (76.63 ± 7.52)% vs. (85.54 ± 6.71)%, the SCC-Ag, CEA, CA125 were significantly higher than those in the good prognosis group: (6.98 ± 2.15) μg/L vs. (4.61 ± 1.37) μg/L, (9.34 ± 2.23) μg/L vs. (5.76 ± 1.87) μg/L, (68.79 ± 12.01) kU/L vs. (49.97 ± 15.22) kU/L, and there were statistical differences ( P<0.05). Logistic regression showed that TVRR, SCC-Ag, CEA and CA125 were significant factors influencing the prognosis of patients with concurrent chemoradiotherapy for cervical cancer ( P<0.05). Among the single indicators, TVRR predicted the highest prognosis AUC, and the combined prognostic AUC of all indicators (0.837, 95% CI 0.761 to 0.920) was higher than any single indicator, with a sensitivity of 81.82% and specificity of 84.52%. The survival curves of TVRR, SCC-Ag, CEA, CA125 between high-risk and low-risk patients showed statistically significant differences ( P<0.05). Conclusions:The changes in tumor volume, SCC-Ag, CEA, CA125 and the prognosis of patients with concurrent radiotherapy and chemotherapy for cervical cancer have a certain correlation. The combined examination of the four in the early stage is expected to become a new approach to clinically predict the prognosis of cervical cancer and make appropriate treatment plans.
ABSTRACT
Objective:To evaluate the prognostic value of combined detection of platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR) and squamous cell carcinoma antigen (SCC) for patients with advanced cervical squamous cell carcinoma undergoing radical radiotherapy.Methods:Clinical data of 127 patients with advanced cervical squamous cell carcinoma who received radical radiotherapy in the Affiliated Tumor Hospital of Nantong University from January 2016 to February 2019 were analyzed retrospectively. The enrolled cases were divided into the survival group and death group according to the survival at the end of 3 years after treatment. The laboratory indexes of peripheral blood were collected before treatment, PLR and NLR were calculated, and the differences of clinical parameters were compared between two groups. The prediction model was established, and the prediction efficiency of PLR, NLR and SCC alone and combined prediction models for 3-year overall survival (OS) in patients with advanced cervical squamous cell carcinoma was compared through the ROC curve. Univariate and multivariate analyses of prognosis were carried out by binary logistic regression model.Results:A total of 127 patients with advanced cervical squamous cell carcinoma were included in the study. There were 96 cases in the survival group and 31 cases in the death group. There were significant differences between two groups in FIGO stage, longest diameter of tumor, lymph node metastasis, PLR, NLR and SCC (all P<0.05). The area under ROC curve (AUC) of PLR, NLR and SCC was 0.660, 0.712 and 0.700, respectively. The AUC of PLR+NLR+SCC combined prediction model was increased to 0.784. Logistic multivariate analysis showed that FIGO Ⅲ, FIGO Ⅳ, lymph node metastasis, PLR≥205.555, NLR≥3.060 and SCC≥6.950 ng/ml were the independent risk factors for 3-year OS in patients with advanced cervical squamous cell carcinoma (all P<0.05). Conclusions:PLR, NLR and SCC have good value in predicting the 3-year OS of patients with advanced cervical squamous cell carcinoma, and the combined prediction model of PLR+NLR+SCC has higher prediction value.
ABSTRACT
Objective:To investigate the correlations of squamous cell carcinoma antigen (SCC), peripheral blood lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) before concurrent chemoradiotherapy with recurrence of cervical cancer after concurrent chemoradiotherapy, and to explore the predictive value of the three above indicators for recurrence.Methods:The data of 90 cervical cancer patients who received concurrent chemoradiotherapy in Shanxi Provincial Cancer Hospital from January to December 2018 were retrospectively analyzed, and the patients were divided into recurrence group and non-recurrence group according to whether they relapsed. The patients' basic information and the levels of SCC, LMR and PLR before concurrent chemoradiotherapy were recorded, and the median follow-up was 17 months (5-24 months). Logistic regression was used to analyze the risk factors affecting the recurrence of cervical cancer after concurrent chemoradiotherapy, the obtained risk factors were used to construct a recurrence prediction model, and the receiver operating characteristic (ROC) curve was used to analyze the predictive value of different indicators for recurrence.Results:Among 90 patients, 26 patients (28.9%) relapsed and 64 patients (71.1%) did not relapse during follow-up. The proportions of patients with tumor maximum diameter ≥ 4 cm [57.7% (15/26) vs. 34.4% (22/64)], lymph node metastasis [53.8% (14/26) vs. 31.2% (20/64)], Karnofsky score 70-75 points [30.8% (8/26) vs. 21.9% (14/64)], Karnofsky score 76-80 points [42.3% (11/26) vs. 17.2% (11/64)], International Federation of Gynecology and Obstetrics (FIGO) stage Ⅳ [42.3% (11/26) vs. 17.2% (11/64)] in the recurrence group were higher than those in the non-recurrence group, and the differences were statistically significant (all P < 0.05). The SCC and PLR in the recurrence group before concurrent chemoradiotherapy were (4.26±0.53) ng/ml and 144.02±11.16, which were higher than those in the non-recurrence group [(2.91± 0.48) ng/ml and 125.18±12.32], and the LMR in the recurrence group before concurrent chemoradiotherapy was 3.93±0.61, which was lower than that in the non-recurrence group (4.68±0.55), and the differences in SCC, PLR and LMR between the two groups were statistically significant (all P < 0.05). The area under the ROC curve of SCC, LMR and PLR before concurrent chemoradiotherapy alone for predicting the recurrence of cervical cancer after concurrent chemoradiotherapy was 0.819 (95% CI 0.708-0.948), 0.763 (95% CI 0.677-0.860) and 0.735 (95% CI 0.590-0.916), and the best cut-off values were 2.13 ng/ml, 4.08 and 133.65. Multivariate logistic regression analysis showed that the tumor maximum diameter ≥4 cm ( OR = 2.116, 95% CI 1.204-3.718), lymph node metastasis ( OR = 2.669, 95% CI 1.022-6.970), FIGO stage Ⅳ ( OR = 2.699, 95% CI 1.359-5.362) and SCC≥2.13 ng/ml ( OR = 4.256, 95% CI 1.194-15.170), LMR≤4.08 ( OR = 5.216, 95% CI 2.987-9.108) and PLR≥133.65 ( OR = 3.256, 95% CI 1.456-7.281) before concurrent chemoradiotherapy were the risk factors for recurrence of cervical cancer after concurrent chemoradiotherapy (all P < 0.05). The area under the ROC curve of the recurrence prediction model constructed by the above risk factors for cervical cancer after concurrent chemoradiotherapy was 0.857 (95% CI 0.744-0.987), the best cut-off value was 157.24, the sensitivity was 0.873, the specificity was 0.845, and the Youden index was 0.718. Conclusions:The recurrence of cervical cancer after concurrent chemoradiotherapy is associated with many factors. The patients with higher SCC, higher PLR and lower LMR before concurrent radiotherapy have higher risk of recurrence. The combined detection of multiple indicators has high value for predicting recurrence.
ABSTRACT
OBJECTIVE: There is no definitive guideline for the significance and cut-off value of squamous-cell carcinoma antigen (SCC-Ag) in cervical cancer. Thus, we analyzed the significance and optimal cut-off value of SCC-Ag for predicting tumor recurrence and patient survival in squamous-cell carcinoma of uterine cervix. METHODS: From January 2010 to October 2016, we enrolled 304 cervical cancer patients with squamous-cell carcinoma staging International Federation of Gynecology and Obstetrics (FIGO) Ib–IVa and treated with definitive chemoradiotherapy (CRT) followed by intra-cavitary radiotherapy (ICR). The cut-off value of SCC-Ag level for tumor recurrence was calculated using the receiver operating characteristic (ROC) curve. The recurrence-free survival (RFS) and overall survival (OS) were assessed using Kaplan-Meier method to estimate the significance of SCC-Ag level. RESULTS: The optimal cut-off value of SCC-Ag level for predicting tumor recurrence was calculated and set at 4.0 ng/mL in the ROC curve. After a median follow-up period of 36.5 months, the 3-year RFS (56.6% vs. 80.2%, p < 0.001) and OS (72.1% vs. 86.8%, p=0.005) were significantly lower in SCC-Ag ≥4 ng/mL arm than in < 4 ng/mL arm. The 3-year locoregional recurrence (17.6% vs. 7.0%, p=0.012), distant metastasis (20.4% vs. 6.9%, p=0.002), and para-aortic recurrence (9.4% vs. 2.1%, p=0.012) rates were significantly higher in SCC-Ag ≥4 ng/mL arm than in SCC-Ag < 4 ng/mL arm. CONCLUSION: Pre-treatment SCC-Ag level higher than 4 ng/mL may be a useful predictor of tumor recurrence in patients with squamous-cell carcinoma of uterine cervix treated with definitive CRT and ICR.
Subject(s)
Female , Humans , Arm , Cervix Uteri , Chemoradiotherapy , Follow-Up Studies , Gynecology , Methods , Neoplasm Metastasis , Obstetrics , Radiotherapy , Recurrence , ROC Curve , Uterine Cervical NeoplasmsABSTRACT
Objective Ubiquitin-proteasome system (UPS) plays a central role in the development of esophageal cancer. However, As the executor of UPS, the expression and clinical significance of detection of serum ubiquitin (UB) in Esophageal Squamous Cell Carcinoma(ESCC) patients have not been fully elucidated. The aim of this study was to investigate the expression and diagnostic value of serum ubiquitin (UB) in ESCC. Methods A total of eighty-eight ESCC patients and forty healthy controls from February 2018 to May 2019 at the Affiliated Jiangyin Hospital of Nantong University were enrolled. Serum UB was measured by ELISA, and serum squamous cell carcinoma antigen (SCC) and carcinoembryonic antigen (CEA) were determined by chemiluminescence method. The ROC curve was used to analyze the diagnostic value of each indicator. Besides, the correlation between serum UB and clinicopathological features of ESCC were analyzed. Results The level of serum UB in ESCC group was significantly higher than that in the control group[(41.96±3.273)ng/ml vs (80.86±7.993)ng/ml, P<0.05]. The level of serum UB in ESCC patients was related to lymphatic metastasis and tumor stage (P<0.05). The sensitivity of UB, SCC, CEA and the three combined diagnosis of ESCC were 65.9%, 52.3%, 51.1%, and 76.1%, respectively. The AUC under the ROC curve were 0.690, 0.677, 0.635, and 0.795, respectively. Conclusion Serum UB is highly expressed in ESCC and is closely related to tumor progression. Combined with SCC and CEA, UB can improve the sensitivity of diagnosis of ESCC and can be used as an effective serological screening biomarker.
ABSTRACT
OBJECTIVE: To investigate the effect of HR-HPV positive,HR-HPV load and SCC-Ag positive on the recurrence of cervical cancer after radical resection.METHODS: The clinical data of cervical cancer patients who underwent radical resection of cervical cancer in People's Hospital of Zengcheng District from January 2010 to January2019 were retrospectively collected.The patients were followed up regularly,and the preoperative HR-HPV positive,loading,the amount of SCC-Ag expression were determined;the recurrence and metastasis of cervical cancer were analyzed,and the value of HR-HPV positive,HR-HPV loading and SCC-Ag in predicting the recurrence and metastasis of cervical cancer were analyzed.RESULTS: A total of 438 patients with cervical cancer were included.There was no significant difference in pathological type,or postoperative Meigs-Brunschwig pathological staging between the recurrence group(n=42)and the non-recurrence group(n=396)(P>0.05).The difference in the proportion of HRHPV positive(40/42 vs. 144/396),HR-HPV loading and SCC-Ag positive(34/42 vs. 64/396)was statistically significant between non-recurrence group and recurrence group(P0.05).Multivariate logistic regression analysis showed that distant metastasis,FIGO staging of cervical cancer,HR-HPV positive,and SCC-Ag were independent factors affecting cervical cancer recurrence(P<0.05).When predicting by individual indicator,the specificity and positive predictive value of HR-HPV positive for predicting cervical cancer recurrence were 99.18% and 95.23% at the highest,and the negative predictive value of HR-HPV was87.37% at the highest.When SCC-Ag was used to predict cervical cancer recurrence,the sensitivity was up to 33.33%.The sensitivity of combined prediction was 64.51%,the specificity was 99.46%,the positive predictive value was97.41%,and the negative predictive value was 94.44%.CONCLUSION: Distant metastasis,FIGO staging,HR-HPV positive,and SCC-Ag are independent factors affecting cervical cancer recurrence.The combination of HR-HPV positive,HR-HPV loading and SCC-Ag has certain value for predicting recurrence of cervical cancer,and the prediction value is the highest.
ABSTRACT
Objective@#To explore the clinical significance of serum squamous cell carcinoma antigen (SCC-Ag) in early cervical squamous cell carcinoma.@*Methods@#The clinicopathological data and follow-up information of 1435 patients with stage ⅠA2-ⅡA cervical squamous cell carcinoma were collected. The correlation between serum SCC-Ag level and clinicopathological feature and prognosis were analyzed. The best cut-off of serum SCC-Ag for predicting pelvic lymph node metastasis and survival of cervical squamous cell carcinoma patients were also identified.@*Results@#The result of univariate analysis showed that The International Federation of Gynecology and Obstetrics (FIGO) staging, tumor size, depth of cervical stromal invasion, lymphovascular space involvement, pelvic lymph node metastasis, common iliac lymph node metastasis and para-aortic lymph node metastasis were significantly related with serum SCC-Ag level (all P<0.05). The result of multivariate logistic regression analysis showed that tumor size, depth of cervical stromal invasion, pelvic lymph node metastasis and common iliac lymph node metastasis were the independent risk factors of preoperative serum SCC-Ag>2.65 ng/ml (all P<0.001). Multivariate Cox regression analysis showed that lymphovascular space involvement, SCC-Ag>3.15 ng/ml, common iliac lymph node metastasis and tumor size >4 cm were the independent prognostic risk factors (all P<0.05). The univariate analysis showed that, the tumor size, FIGO stage, depth of cervical stromal invasion and SCC-Ag level were significantly related with the recurrence of 1 096 patients without postoperative high risk factors (all P<0.05). Multivariate logistic regression analysis showed that FIGO stage (OR=1.671) and SCC-Ag>2.65 ng/ml (OR=4.490) were the independent risk factors for recurrence (both P<0.05). The best cut off of SCC-Ag for predicting early postoperative cervical lymph node metastasis of cervical squamous cell carcinoma was 2.65 ng/ml, the sensitivity was 60.8%, the specificity was 71.8%. The best cut off of SCC-Ag for predicting prognosis of cervical squamous cell carcinoma was 3.15 ng/ml, the sensitivity was 53.5%, the specificity was 71.1%.@*Conclusions@#Preoperative serum squamous cell carcinoma antigen is an independent prognostic risk factor of survival of patients with early cervical squamous cell carcinoma, and is significantly related with recurrence of patients without postoperative high-risk factors. It can be used as a reference factor for postoperative adjuvant radiotherapy.
ABSTRACT
Objective To explore the changes of serum interleukin-13 (IL-13) and squarnous cell carcinoma antigen (SccAg) levels in pediatric asthma and its clinical significance.Methods 45 children with pediatric asthma were selected as observation group,45 healthy children at the same time were selected as control group.IL-13 and SccAg levels in the two groups were detected by ELISA.The correlation between the serum IL-13,SccAg levels and pediatric asthma was analyzed.Results In the observation group,the IL-13,SccAg levels at the attack stage were (148.96 ± 24.56) ng/L,(3.36 ± 0.69) μg/L,respectively,the IL-13,SccAg levels at the remission stage were (90.65 ± 20.14)ng/L,(2.58 ± 0.34) μg/L,respectively,which in the control group were (76.48 ± 17.54) ng/L,(2.30 ± 0.36) μg/L,respectively,the differences were statistically significant (F =5.36,6.39,all P ＜ 0.05).In the observation group,the IL-13,SccAg levels in the patients with moderate or severe disease were (135.48 ± 21.69)ng/L,(2.86 ± 0.36) μg/L,respectively,the IL-13,SccAg levels in the patients with mild disease were (160.38 ± 22.45) ng/L,(3.30 ±0.41) μg/L,respectively,which in the control group were (76.48 ± 17.54) ng/L,(2.30 ± 0.36) μg/L,respectively,the differences were statistically significant (F =5.78,6.78,all P ＜ 0.05).The serum IL-13 and SccAg levels had significantly positive correlation with pediatric asthma during the attack stage and remission stage (r =0.982,0.965,all P ＜ 0.05).Conclusion The serum IL-13 and SccAg levels have certain association with the incidence of asthma,which play an important role in determining the development and reorientation of asthma.
ABSTRACT
Objective To investigate the values of squamous cell carcinoma antigen (SCCAg),tumor abnormal protein (TAP),carcinoembryonic antigen (CEA) in evaluating the efficacy of neoadjuvant chemotherapy for cervical cancer.Methods A total of 100 patients with cervical cancer treated by neoadjuvant chemotherapy were selected from September 2015 to September 2017 in our hospital,and 100 healthy persons were selected as the control group at the same time.The serum levels of SCCAg,TAP and CEA were detected and the relationships between the levels of SCCAg,TAP,CEA and the efficacy of neoadjuvant chemotherapy were analyzed.Results The serum levels of SCCAg [(4.95 ±0.65) μg/L vs.(0.22 ±0.04) μg/L],TAP [(175.21 ± 25.42) μm2 vs.(75.45 ± 9.98) μm2],CEA [(35.65 ± 4.23) ng/ml vs.(1.26 ± 0.34) ng/rnl] in patients with cervical cancer were significantly higher than those of control group,and the differences were statistically significant (t =75.382,P ＜ 0.001;t =62.215,P ＜ 0.001;t =55.452,P ＜ 0.001).Three months after neoadjuvant chemotherapy for 100 cervical cancer patients,complete remission (CR) was achieved in 6 cases (6.00％),partial remission (PR) in 50 cases (50.00％),stable disease (SD) in 26 cases (26.00％),and progression disease (PD) in 18 cases (18.00％).The SCCAg,TAP and CEA levels of patients with CR [(2.12 ± 0.32) μg/L vs.(4.90 ± 0.52) μg/L,(133.12 ± 14.22) μm2 vs.(175.12 ± 24.32) μm2,(10.34 ± 2.42) ng/ml vs.(38.21 ± 7.82) ng/ml] and PR after chemotherapy were significantly lower than those before chemotherapy [(3.22 ± 0.47) μg/L vs.(4.94 ± 0.53) μg/L,(145.22 ± 17.77) μm2 vs.(179.52 ± 25.53) μm2,(16.75 ± 3.02) ng/ml vs.(39.12 ± 7.92) ng/ml],and the differences were statistically significant (t =11.153,P ＜ 0.001;t =3.562,P =0.004;t =8.340,P ＜ 0.001;t =17.169,P ＜ 0.001;t =7.797,P ＜ 0.001;t =18.662,P ＜ 0.001).The above indicators of patients with PD after chemotherapy were significantly higher than those before chemotherapy [(7.21 ± 0.84) μg/Lvs.(5.06±0.57) μg/L,(213.21 ±29.64) μm2vs.(171.56±26.87) μm2,(46.64± 5.12) ng/ml vs.(35.75 ± 7.88) ng/ml],and the differences were statistically significant (t =8.986,P ＜ 0.001;t =4.417,P ＜0.001;t =4.917,P ＜0.001).The differences of the above indicators before and after chemotherapy in patients with SD were not statistically significant [(5.03 ± 0.57) μg/L vs.(4.97 ± 0.55) μg/L;(175.51 ± 23.37) μm2 vs.(176.27 ± 26.55) μm2;(35.26 ± 7.34) ng/ml vs.(37.04 ± 7.73) ng/ml;t =0.386,P=0.701;t=0.110,P=0.913;t=0.851,P=0.399].The results of receiver operating characteristic (ROC) curve analysis showed that the sensitivity,specificity and accuracy of SCCAg in evaluating the neoadjuvant chemotherapy for cervical cancer were 85.71％,81.82％,84.00％,those of TAP were 82.14％,77.27％,80.00％,those of CEA were 78.57％,77.27％,78.00％,and those of the combined detection were 96.43％,95.45％,96.00％.The sensitivity,specificity and accuracy of the combined detection were significantly higher than those of the three alone,and the differences were statistically significant (x2 =14.434,P＜0.001,x2 =15.421,P＜0.001,x2 =21.741,P＜0.001).Conclusion The serum levels of SCCAg,TAP and CEA in patients with cervical cancer are decreased after neoadjuvant chemotherapy.Their level changes can be used as important indicators to evaluate the efficacy of chemotherapy,and the combination of the three has better evaluation efficiency,which is worth for further clinical promotion.
ABSTRACT
OBJECTIVE: The objective of this study was to determine the optimal cutoff level of serum squamous cell carcinoma antigen (SCC-Ag) to detect recurrent cervical squamous cell carcinoma during post-treatment surveillance. METHODS: Between January 2000 and July 2014, a total of 158 women with cervical squamous cell carcinoma were treated with radiotherapy with or without concurrent chemotherapy at our department. A total of 1,550 serum SCC-Ag tests performed during post-treatment surveillance of the 158 patients were included in this retrospective study. RESULTS: During post-treatment surveillance, 53 patients were diagnosed as having recurrent cervical cancer based on biopsy or a radiological test showing progression of a lesion. Receiver operating characteristic (ROC) curve for serum SCC-Ag to diagnose recurrent cervical squamous cell carcinoma showed that the area under the ROC curve was 0.914 (95% confidence interval, 0.887–0.942; P < 0.001). The best cutoff value for serum SCC-Ag to obtain the highest Youden's index was ≥2 ng/mL (sensitivity, 80.2%; specificity, 94.6%). CONCLUSION: Serum SCC-Ag test was helpful in detecting recurrent cervical squamous cell carcinoma during post-treatment surveillance, and the optimal cutoff value was ≥2 ng/mL. The researchers recommend active imaging studies, when serum SCC-Ag level ≥2 ng/mL during post-treatment surveillance.
Subject(s)
Female , Humans , Biopsy , Carcinoma, Squamous Cell , Drug Therapy , Epithelial Cells , Radiotherapy , Recurrence , Retrospective Studies , ROC Curve , Sensitivity and Specificity , Uterine Cervical NeoplasmsABSTRACT
Objective To investigate the clinical value of tumor specific grow th factor(TSGF),neuron specific enolase(NSE),cytokeratin 19 fragment(CYFRA21-1),squamous cell carcinoma antigen(SCCAg)in the diagnosis of lung cancer.Methods 20 patients with lung cancer,42 patients with lung benign diseases and 54 healthy people undergoing the physical examination in this hospital from September 2014 to November 2016 were served as the lung cancer group,benign diseases group and healthy control group respectively.The Abbott microparticle chemiluminescence instrument was used to detect CYFRA21-1 and SCCA levels,the Roche electrochemical luminescence instrument was used to detect the NSE level and the TSGF level was de-tected by using the Olympus 5400 biochemical analyzer.Then the detection results were statistically analyzed. Results The levels of serum TSGF and NSE in the lung cancer group were higher than those in the lung be-nign diseases group and healthy control group,and the differences were statistically significant(P< 0.05). The serum CYFRA21-1 level of the lung benign disease group was higher than that in the healthy control group(P<0.05).The sensitivity and specificity of TSGF,NSE,CYFRA21-1 and SCCAg combined detection were 90.00% and 93.00% respectively.The area under the ROC curve was 0.959.Conclusion TSGF posses-ses wide spectrum marker characteristics,has a certain value for screening lung cancer,moreover its combined detection with NSE,CYFRA21-1 and SCCAg can increase the accuracy in diagnosis of lung cancer.
ABSTRACT
Objective To determine the levels of plasma M-CSF in cervical cancer patients and cervical intraepitheliai neoplasia(CIN)patients,and to discuss the diagnostic utility of M-CSF in the development of cervi-cal cancer. Methods Forty-nine cases of cervical cancer,60 cases of CIN and 40 healthy controls were selected from June 2014 to June 2016. Plasma levels of M-CSF and SCC-Ag were determined by using ELISA and MEIA, respectively. Results Significantly different concentrations of M-CSF and SCC-Ag were observed in patients with cervical cancer compared to the healthy controls and CIN patients(P<0.01,respectively). Significant difference in plasma M-CSF level between the healthy controls and benign lesion patients were also found(P<0.05).However, no significant difference in SCC-Ag was found between the healthy controls and benign lesion patients. SCC-Ag combined M-CSF could obviously increase the detection rate of cervical cancer,without increasing the false posi-tive rate. The level of M-CSF in patients with cervical cancer and high grade of CIN reduced to the normal level, with significant difference before and after surgery(P<0.05).Meanwhile,the level of SCCAg in CIN patients was significantly reduced before and after surgery(P<0.05).Conclusions This study suggests the potential utility of M-CSF as a good candidate for a serum marker of cervical cancer,as well as benign lesions of this organ(CIN), and M-CSF may also be use to predict the outcome of CIN.
ABSTRACT
Objective To explore the diagnostic value of carcino embryonic antigen (CEA),squamous cell carcinoma antigen(SCC),human papilloma virus-E7 (HPV-E7) in cervical carcinoma.Methods A total of 107 cases of women patients treated in hospital from July 2013 to July 2015 accorded to the pathological examination results were divided into cervical cancer group 60 cases and CIN group 47 cases,another 50 cases of healthy people were selected as control group, and serum expression levels of HPV-E7, CEA and SCC in the three groups were detected by enzyme-linked immunosorbent assay.Results The serum HPV-E7, CEA and SCC in cervical cancer group were significantly higher than those in CIN group and control group (P<0.05).There was no significant difference in serum HPV-E7, CEA and SCC between CIN group and control group.The levels of serum HPV-E7, CEA and SCC in stage I-II were significantly lower than those of stage III-IV in patients with cervical cancer, and the difference with statistically significant between two groups(P<0.05).The area under the ROC of HPV-E7 was significantly higher than that of CEA and SCC (Z=2.914,2.951, P<0.05), and there was no significant difference in the area under the ROC between CEA and SCC (Z=1.580,P=0.057).Conclusion The serum HPV-E7, CEA and SCC in cervical cancer patients are significantly higher, the diagnosis value of HPV-E7 is higher which is expected to become one of the effective indicators of cervical cancer diagnosis.
ABSTRACT
Objective The aim of this study was to assess the clinical value of pro-gastrin releasing peptide (ProGRP) , squamous cell carcinoma antigen (SCC-Ag), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) and carcino-embryonic antigen (CEA) in the diagnosis and clinical stage of lung cancer in Chinese patients.Methods Patients with lung cancer and benign lesions confirmed by pathology were enrolled in Peking Union Medical College Hospital from January 2013 to October 2014.The serum levels of four tumor markers (ProGRP, SCC-Ag, Cyfra21-1 and CEA) were measured using immunoassays before treatment.The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and the areas under the receiver operating characteristic curve (AUCROC) of these four tumor biomarkers were analyzed for the diagnosis of lung cancer.Results A total of 134 patients were finally analyzed, including 73 patients with lung cancer and the other 61 patients with benign lung disease.The diagnostic sensitivity of serum Cyfra21-1 to lung cancer was 67.1％, the specificity 45.1％, the AUCROC 0.658.The diagnostic sensitivity of the panel including ProGPR, Cyfra21-1 and CEA to lung cancer was 75.3％ , the specificity 57.4％ , the AUCROC 0.702.In the lung cancer group, the AUCROC of ProGRP over 65 ng/L to diagnose small cell lung cancer was 0.954;the AUCROC of SCC-Ag over 1.5 μg/L to diagnose squamous cell lung cancer was 0.788;the AUCROC of Cyfra21-1 to diagnose non-squamous-non-small-cell lung cancer was 0.716.In small cell lung cancer patients, the level of ProGRP in limited-disease small cell lung cancer (LD-SCLC) were significantly higher than that in extensive-disease small cell lung cancer (ED-SCLC) (P =0.005).Conclusion This panel of serum tumor markers including ProGRP, Cyfra21-1 and CEA improves the diagnostic specificity and sensitivity in patients with high-risk lung cancer.The serum CEA level of advanced lung cancer patients is significantly increased.The high level of serum ProGRP predicts the ED-SCLC.
ABSTRACT
Objective To investigate expression of cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients with lung metastasis before treatment and their prognostic value. Methods The pretreatment serum expression levels of SCC-Ag and CYFRA21-1 of 72 cervical cancer patients with lung metastasis were measured. Survival rate analysis and Cox proportional hazard model were performed to evaluate the prognostic significance of two pretreatment variables. Results The media survival time (MST) of 72 patients was 14 months, and 38 (52.8 %) patients with pulmonary metastasis occurred in 1 year of treatment. The pretreatment serum SCC-Ag and CYFRA21-1 levels in the patients with tumor diameter over 4 cm or with squamous cell carcinoma were higher than those in the other patients (all P3.3 mg/L) was higher than that in the negative group (13 months vs 19 months, P1.5 mg/L) was also higher than that in the negative group (14 months vs 21 months, P<0.05). The result of Cox regression analysis showed that the tumor diameter (OR = 11.6, P = 0.01), pretreatment serum SCC-Ag (OR= 4.2, P= 0.01) and CYFRA21-1 (OR= 8.2, P= 0.05) levels were independent prognostic factors of overall survival. Conclusion Pretreatment CYFRA 21-1 and SCC-Ag levels may be considered as useful prognostic indicators for cervical cancer patients with lung metastasis.
ABSTRACT
Objective To explore the value of detecting serum cytokeratin 19 fragmen 21-1 (CYFRA21-1) and squamous cell carcinoma antigen (SCCAg) in the diagnosis of patients with nasopharyngeal carcinoma.Methods 79 patients with nasopharyngeal carcinoma from October 2013 to October 2015 as case group and 145 patients with nasopharyngeal chronic inflammation as control group were collected.The CYFRA21-1 level was detected by the electrochemical luminescence immunoassay and the SCCAg level was detected by the enzymoimmunoassay.Comparisons of diagnostic value of CYFRA21-1 and SCCAg to nasopharyngeal carcinoma were conducted according to pathological diagnosis.Results The serum CYFRA21-1 and SCCAg levels in case group were (12.37±1.65) g/L and (1.65±0.37) ng/ml,and the control group were (4.26±1.99) g/L and (1.22±0.45) ng/ml,with statistically significant differences (t =8.093,P =0.002;t =4.287,P =0.043).The sensitivity,specificity,positive predictive value,negative predictive value and accuracy of CYFRA21-1 combined with SCCAg in the diagnosis of nasopharyngeal carcinoma were higher than those of CYFRA21-1 and SCCAg respectively,and the difference all were statistically significant (all P ＜ 0.05).Conclusion Detecting serum CYFRA21-1 combined with SCCAg in the diagnosis of nasopharyngeal carcinoma has high sensitivity and good specificity,which can significantly improve the diagnostic accuracy.
ABSTRACT
Objective To explore the clinical significance of the serum cell-free DNA on early diagnosis and prognostic value of patients with cervical carcinoma. Methods Forty-five patients with cervical carcinoma and 50 healthy women from May 2012 to February 2014 were selected from the Central Hospital of Ezhou. Serum cell-free DNA(cf-DNA),carbohydrate antigen125(CA125),carbohydrate antigen19-9(CA19-9), squamous cell carcinoma antigen( SCC ),β-human chorionic gonadotropin( β--HCG ) were detected by electrochemiluminescence analyzer. Results The levels of serum cf-DNA,SCC,β-HCG of patients in the cervical carcinoma group were(178. 8 ± 43. 4)μg/ L,(0. 7 ± 0. 3)μg/ L,(1. 3 ± 0. 4)kU/ L respectively, higher than those in health women((1 354. 7 ± 267. 2)μg/ L,(1. 4 ± 0. 4)μg/ L,(5. 2 ± 0. 6)kU/ L),and the differences were significant(t = 30. 690,9. 709,37. 614;P < 0. 001). Serum cf-DNA level of patients with Ⅱ-Ⅲperiod cervical carcinoma was(2 538. 8 ± 775. 3)μg/ L,higher than patients with Ⅰ period((1 244. 7 ± 253. 6)μg/ L;t = 8. 191,P < 0. 001). The area under the curve of ROC of serum cf-DNA,CA125,CA19-9, SCC,β-HCG were 0. 951 6,0. 638 2,0. 614 4,0. 805 7,0. 753 1 respectively and the AUC of serum cf-DNA was the largest. The sensibility,specificity,accuracy of cf-DNA were 75. 56% ,99. 13% ,93. 36% and 28. 32% , 93. 24% ,64. 26% in terms of CA125. Meanwhile,the sensibility,specificity,accuracy of CA19-9 were 19. 75% , 94. 47% ,67. 28% and 38. 87% ,88. 53% ,80. 16% in terms of SCC. The sensibility,specificity,accuracy of β-HCG were 43. 28% ,86. 21% ,77. 83% respectively. Conclusion Serum cf-DNA has high sensibility, specificity and accuracy in early diagnosis and prognostic value of patients with cervical carcinoma and it is worthy of clinical promotion.
ABSTRACT
Objective To establish a rapid and sensitive chemiluminescence immunoassay for detecting squamous cell carcinoma antigen (SCCA)in human serum.Methods Fluorescein isothiocyanate (FITC)and N-(aminobutyl)-N-(ethylisoluminol)(ABEI) were used to label two different monoclonal antibodies of anti-SCCA.SCCA in serum combined with labeled antibodies and formed a sandwiched immunoreaction.After adding the substrate solution,the relative light unit of ABEI was measured.Magnetic particles coated with anti-FITC antibody were used as solid separation carrier.Results The results demonstrated that the method was linear to 22 ng/mL with a detection limit of 0.025 ng/mL.The coefficient of variation (CV)was less than 6% and 7% for intra-assay and inter-assay precision,respectively.Compared with the commercial kit,the proposed method showed a correlation of 0.990 1.Conclu-sion chemiluminescence immunoassay based on magnetic particles displays acceptable performance for quantification of SCCA and is appropriate for use in clinical diagnosis.
ABSTRACT
Objective To explore the clinical value of tumor marker squamous cell carcinoma antigen(SCCA) ,tissue polypeptide specific antigen(TPS) ,neuron‐specific enolase(NSE) ,cytokeratin fragment 19(CYFRA21‐1) detections in the patient with lung cancer .Methods 70 patient with newly diagnosed lung cancer(including 26 cases of squamous cell carcinoma ,23 cases of adenocar‐cinoma and 21 cases of small cell carcinoma) ,40 cases of lung benign diseases and contemporaneous 30 individuals undergoing the physical examination were randomly selected as the lung cancer group ,lung benign disease group and healthy control group respec‐tively .Serum tumor markers of SCCA ,TPS ,NSE and CYFERA21‐1 were detected in all cases .Then the detection results were per‐formed the statistical analysis .Results The levels of SCCA ,TPS ,NSE and CYFERA21‐1 in the lung cancer group were significant‐ly higher than those in the lung benign diseases group and healthy control group ,the differences were statistically significant (P0 .05) .The combination detection of SCCA , TPS ,NSE and CYFERA21‐1 greatly increased the sensitivity and accuracy for diagnosing lung cancer .Conclusion The combina‐tion detection of SCCA ,TPS ,NSE and CYFERA21‐1 has very high clinical value for the diagnosis ,pathological typing and assisted clinical therapy of lung cancer .